Pfizer Inc. (PFE)
| Market Cap | 145.13B |
| Revenue (ttm) | 59.38B |
| Net Income (ttm) | 4.25B |
| Shares Out | 5.67B |
| EPS (ttm) | 0.74 |
| PE Ratio | 34.40 |
| Forward PE | 9.82 |
| Dividend | $1.72 (6.72%) |
| Ex-Dividend Date | Jan 24, 2025 |
| Volume | 21,407,742 |
| Open | 25.70 |
| Previous Close | 25.89 |
| Day's Range | 25.58 - 26.09 |
| 52-Week Range | 24.48 - 31.54 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 32.31 (+26.16%) |
| Earnings Date | Jan 28, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]
Financial Performance
In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $32.31, which is an increase of 26.16% from the latest price.
News
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, ...
Roam For the Holidays: Grindr Offers Free Access to Their Popular Travel Feature
WEST HOLLYWOOD, Calif.--(BUSINESS WIRE)--From December 22 to January 2, people on Grindr across the globe can experience Roam, a popular new feature, free of charge.
Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis)
Pfizer Inc.'s technical indicators have shifted from bullish to bearish, with the stock now trading below its 30-week EMA and showing bearish momentum. Volume analysis indicates recent institutional s...
Is Pfizer Stock Undervalued?
Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 billion...
Final Trade: GOOG, SAIA, X, PFE
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Pfizer climbs 4% on 2025 outlook
Evan David Seigerman, BMO analyst, joins 'Closing Bell Overtime' to talk Pfizer's 2025 outlook.
Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks
Shares of Pfizer Inc. PFE are making a large move higher Tuesday. But the stock has run into resistance.
Pfizer Inc. (PFE) Full-Year 2025 Financial Guidance Conference Call (Transcript)
Pfizer Inc. (NYSE:PFE) Full-Year 2025 Financial Guidance Conference Call December 17, 2024 8:30 AM ET Company Participants Francesca DeMartino - Chief IRO and SVP Albert Bourla - Chairman and CEO Dav...
Pfizer Stock Rises as 2025 Outlook in Line With Expectations
Pfizer (PFE) shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.
Guggenheim: Can see Pfizer reaching $10 billion in sales by 2030
Vamil Divan, Guggenheim Securities analyst, joins 'Squawk on the Street' to discuss Pfizer's guidance, how optimistic Divan is on Pfizer's product pipeline, and some of the complaints Pfizer has heard...
Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025
On Tuesday, Pfizer Inc. PFE released its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion compared to a consensus of $63.28 billion.
Pfizer Sees 2025 Revenue in Line With Wall Street Views
Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of federal drug benefits.
Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion
The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.
Pfizer forecasts 2025 profit in line with expectations
Drugmaker Pfizer on Tuesday said it was expecting its 2025 profits to be nearly in line with Wall Street expectations as it seeks to fend off criticism over its turnaround strategy from activist hedge...
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer 2025 Financial Guidance press release.
Insurer stocks fall after Trump says 'we're going to knock out the middleman'
Shares of health insurers operating pharmacy benefit managers fell on Monday after U.S. President-elect Donald Trump called them middlemen who drive up costs and said he plans to eliminate their role.
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Pfizer Inc. PFE will conduct an investor call on Tuesday to provide full-year 2025 financial guidance.
Pfizer: Lowest Levels In A Decade Is An Opportunity With A Dividend Yield Exceeding 6.5%
Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling value play. Despite revenue declines and potential regulatory risks, Pfizer re...
Pfizer: Irrational Anti-Vaccine Fear
Pfizer's stock has become appealing due to irrational vaccine fears. Market fears about RFK Jr.'s potential anti-vaccine stance are likely overblown, as neither he nor Trump have indicated plans to bl...
Reader Mailbag: Is Pfizer (PFE) a Good Deal Right Now?
November was an interesting month for pharmaceutical companies in general. President-elect Trump officially announced that Robert F.
Pfizer Declares First-Quarter 2025 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.43 for the first-...
Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) today announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE® (palbocicl...
Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with significant Seagen acquisition integration ongoing. Q3 2024 results show 32% YoY revenue inc...
Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)
I upgrade Pfizer to "Strong Buy" due to its undervaluation, strong pipeline, and operational growth despite recent stock price declines. Pfizer's Q3 FY2024 earnings showed significant revenue and EPS ...
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, D...